|
1
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mithoowani H and Febbraro M:
Non-small-cell lung cancer in 2022: A review for general
practitioners in oncology. Curr Oncol. 29:1828–1839. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ricotti A, Sciannameo V, Balzi W,
Roncadori A, Canavese P, Avitabile A, Massa I and Berchialla P:
Incidence and prevalence analysis of non-small-cell and small-cell
lung cancer using administrative data. Int J Environ Res Public
Health. 18:90762021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alexander M, Kim SY and Cheng H: Update
2020: Management of non-small cell lung cancer. Lung. 198:897–907.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: NCCN guidelines insights: Non-small cell lung cancer,
version 2.2021. J Natl Compr Canc Netw. 19:254–266. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Remon J, Soria JC and Peters S; ESMO
Guidelines Committee. Electronic address, : simpleclinicalguidelines@esmo.org:
Early and locally advanced non-small-cell lung cancer: An update of
the ESMO clinical practice guidelines focusing on diagnosis,
staging, systemic and local therapy. Ann Oncol. 32:1637–1642. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Puri S, Saltos A, Perez B, Le X and Gray
JE: Locally advanced, unresectable non-small cell lung cancer. Curr
Oncol Rep. 22:312020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ulas EB, Dickhoff C, Schneiders FL, Senan
S and Bahce I: Neoadjuvant immune checkpoint inhibitors in
resectable non-small-cell lung cancer: A systematic review. ESMO
Open. 6:1002442021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sławiński G, Wrona A, Dabrowska-Kugacka A,
Raczak G and Lewicka E: Immune checkpoint inhibitors and cardiac
toxicity in patients treated for non-small lung cancer: A review.
Int J Mol Sci. 21:71952020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Spigel DR, Faivre-Finn C, Gray JE, Vicente
D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R,
Quantin X, et al: Five-year survival outcomes from the PACIFIC
trial: Durvalumab after chemoradiotherapy in stage III
non-small-cell lung cancer. J Clin Oncol. 40:1301–1311. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen T, Ning J, Campisi A, Dell'Amore A,
Ciarrocchi AP, Li Z, Song L, Huang J, Yang Y, Stella F and Luo Q:
Neoadjuvant PD-1 inhibitors and chemotherapy for locally advanced
NSCLC: A retrospective study. Ann Thorac Surg. 113:993–999. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhai H, Li W, Jiang K, Zhi Y and Yang Z:
Neoadjuvant nivolumab and chemotherapy in patients with locally
advanced non-small cell lung cancer: A retrospective study. Cancer
Manag Res. 14:515–524. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu YL, Planchard D, Lu S, Sun H, Yamamoto
N, Kim DW, Tan DSW, Yang JC, Azrif M, Mitsudomi T, et al: Pan-Asian
adapted clinical practice guidelines for the management of patients
with metastatic non-small-cell lung cancer: A CSCO-ESMO initiative
endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 30:171–210.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shamji FM and Beauchamp G: Assessment of
operability and resectability in lung cancer. Thorac Surg Clin.
31:379–391. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cascone T, William WN Jr, Weissferdt A,
Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L,
Reuben A, et al: Neoadjuvant nivolumab or nivolumab plus ipilimumab
in operable non-small cell lung cancer: The phase 2 randomized
NEOSTAR trial. Nat Med. 27:504–514. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Casarrubios M, Cruz-Bermúdez A, Nadal E,
Insa A, García Campelo MDR, Lázaro M, Dómine M, Majem M,
Rodríguez-Abreu D, Martínez-Martí A, et al: Pretreatment tissue TCR
repertoire evenness is associated with complete pathologic response
in patients with NSCLC receiving neoadjuvant chemoimmunotherapy.
Clin Cancer Res. 27:5878–5890. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
National Institutes of Health and National
Cancer Institute, . Common terminology criteria for adverse events
(CTCAE) version 4.0. Published:. May 28–2009.https://evs.nci.nih.gov/ftp1/CTCAE/About.html
|
|
20
|
Duan H, Wang T, Luo Z, Tong L, Dong X,
Zhang Y, Afzal MZ, Correale P, Liu H, Jiang T and Yan X:
Neoadjuvant programmed cell death protein 1 inhibitors combined
with chemotherapy in resectable non-small cell lung cancer: An
open-label, multicenter, single-arm study. Transl Lung Cancer Res.
10:1020–1028. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen S, Zhao Z and Long H: Application of
neoadjuvant immuno-chemotherapy in NSCLC. Zhongguo Fei Ai Za Zhi.
24:284–292. 2021.(In Chinese). PubMed/NCBI
|
|
22
|
Hou X, Shi X and Luo J: Efficacy and
safety of camrelizumab (a PD-1 inhibitor) combined with
chemotherapy as a neoadjuvant regimen in patients with locally
advanced non-small cell lung cancer. Oncol Lett. 24:2152022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y and Zhang Z: The history and
advances in cancer immunotherapy: Understanding the characteristics
of tumor-infiltrating immune cells and their therapeutic
implications. Cell Mol Immunol. 17:807–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Emens LA and Middleton G: The interplay of
immunotherapy and chemotherapy: Harnessing potential synergies.
Cancer Immunol Res. 3:436–443. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Salas-Benito D, Pérez-Gracia JL,
Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E,
López-Picazo JM, Sanmamed MF and Melero I: Paradigms on
immunotherapy combinations with chemotherapy. Cancer Discov.
11:1353–1367. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Provencio M, Nadal E, Insa A,
García-Campelo MR, Casal-Rubio J, Dómine M, Majem M,
Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, et al:
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell
lung cancer (NADIM): An open-label, multicentre, single-arm, phase
2 trial. Lancet Oncol. 21:1413–1422. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mielgo-Rubio X, Uribelarrea EA, Cortés LQ
and Moyano MS: Immunotherapy in non-small cell lung cancer: Update
and new insights. J Clin Transl Res. 7:1–21. 2021.PubMed/NCBI
|
|
28
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III non-small-cell
lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hamada A, Soh J, Hata A, Nakamatsu K,
Shimokawa M, Yatabe Y, Oizumi H, Tsuboi M, Horinouchi H, Yoshino I,
et al: Phase II study of neoadjuvant concurrent
chemo-immuno-radiation therapy followed by surgery and adjuvant
immunotherapy for resectable stage IIIA-B (Discrete N2)
non-small-cell lung cancer: SQUAT trial (WJOG 12119L). Clin Lung
Cancer. 22:596–600. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dickhoff C, Senan S, Schneiders FL,
Veltman J, Hashemi S, Daniels JMA, Fransen M, Heineman DJ, Radonic
T, van de Ven PM, et al: Ipilimumab plus nivolumab and
chemoradiotherapy followed by surgery in patients with resectable
and borderline resectable T3-4N0-1 non-small cell lung cancer: The
INCREASE trial. BMC Cancer. 20:7642020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao ZR, Yang CP, Chen S, Yu H, Lin YB,
Lin YB, Qi H, Jin JT, Lian SS, Wang YZ, et al: Phase 2 trial of
neoadjuvant toripalimab with chemotherapy for resectable stage III
non-small-cell lung cancer. Oncoimmunology. 10:19960002021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aguado C, Chara L, Antoñanzas M, Matilla
Gonzalez JM, Jiménez U, Hernanz R, Mielgo-Rubio X, Trujillo-Reyes
JC and Couñago F: Neoadjuvant treatment in non-small cell lung
cancer: New perspectives with the incorporation of immunotherapy.
World J Clin Oncol. 13:314–322. 2022. View Article : Google Scholar : PubMed/NCBI
|
